Epstein-Barr virus (EBV)-positive B-cell lymphoproliferative disease develops in severe combined immunodeficient (SCID) mice inoculated with peripheral blood mononuclear cells (PBMC) from EBV + individuals (SCID/hu mice). In this study, we investigated the contribution of EBV reactivation and de novo infection of B lymphocytes to tumor outgrowth in SCID/hu mice. Evaluation of BZLF-1, an early EBV activation transcript, in cells recovered from the mouse peritoneal cavity within 16 days following PBMC transfer did not reveal EBV reactivation, while BZLF-1 expression was only detected in tumor masses or in vitro established lymphoblastoid cell lines. To confirm these data by a different strategy, we coinjected PBMC from seropositive donors with purified B cells from seronegative donors of different sex. Fluorescence in situ hydridization analysis of the resulting tumor masses disclosed that the overwhelming majority of lymphoma cells originated from the seropositive donor, implying that no substantial in vivo production and transmission of virus had occurred. Further, treatment of SCID/hu mice with ganciclovir did not prevent lymphoma development. Our results suggest that in the SCID/ hu mouse, early EBV replication and secondary infection of bystander B cells does not occur, and that the direct outgrowth of the transformed B lymphocytes present within the PBMC inoculum is the predominant mechanism, which leads to lymphoma generation in this experimental model.
Introduction
The Epstein-Barr virus (EBV), a B-lymphotropic herpesvirus carried by the majority of humans as a lifelong asymptomatic infection, is implicated in the pathogenesis of at least three malignant B-cell disorders: Burkitt's lymphoma, classic Hodgkin's disease, and post-transplantation lymphoproliferative disease (PTLD) seen in immunosuppressed allograft recipients, which comprises a variety of B-cell disorders ranging from plasmacytic hyperplasia to malignant lymphoma. 1 During the acute phase of the infection, B cells express an array of 'early' or 'lytic' antigens, including BZLF-1. Subsequently, the virus establishes a chronic infection during which very few B lymphocytes harbor the virus and express only a part of the 'late' EBV antigenic profile, among which EBER-1 is the most abundant. 1, 2 In contrast, ex vivo or in vitro derived lymphoblastoid cell lines (LCL) constitutively express six nuclear antigens (EBNA-1, -2, -3A, -3B, -3C, -LP), three latent membrane proteins (LMP-1, -2A, -2B) and two small nuclear, nonpolyadenylated RNAs (EBER-1, -2); this form of latency is termed as latency III (1) . As far as T-cell responses are concerned, virus-host interactions are very complex. On the one hand, since periodical reactivation of EBV replication occurs in seropositive subjects, 3 HLA class I-restricted CD8 + cytotoxic T lymphocytes play a major role in the control of latent EBV infection, by virtue of their ability to recognize viral antigens associated with B-cell transformation; 4, 5 on the other hand, CD4 + T cells may play a key role in reactivation of latent EBV infection. 6 The mutant C.B-17 mouse strain has a chromosome 16 defect involving the V-D-J recombinase system that prevents correct T-cell receptor and Ig gene rearrangement, and translates into complete absence of T and B lymphocytes and severe combined immunodeficiency (SCID). 7, 8 SCID mice injected intraperitoneally (i.p.) with peripheral blood mononuclear cells (PBMC) from EBV-seropositive donors (SCID/hu mice) develop tumors formed by B cells harboring EBV; 9 this model has represented a useful tool to dissect the events involved in human lymphomagenesis, and allowed remarkable advancements in the understanding of the mechanisms underlying this process. Of note, in the SCID/hu model, lymphoma generation strongly depends on the presence of T lymphocytes; in fact, tumor masses only develop when T cells are coinjected with EBV-infected precursors, and cyclosporine administration to the animals paradoxically prevents tumor development. 10, 11 In a human setting, several observations also point to an involvement of activated T cells in non-Hodgkin's B-cell lymphoma generation, and the correlation of gastrointestinal B cell lymphomas with Helicobacter pylori-specific T lymphocytes is well-known. 12 The mechanisms underlying this T-cell-mediated promotion of lymphomagenesis are far from clear; in particular, it is not known whether lymphoma originates from the very few latently infected B-cell precursors injected, which are calculated in a range of 2-60 10 6 B lymphocytes, 13 or whether EBV reactivation and virus spread to bystander B cells also occurs. In this regard, it has recently been demonstrated that activated T lymphocytes are able in vitro to reactivate EBV replication in latently infected B cells, as shown by BZLF-1 expression. 6 In this latter paper, it is postulated that in the SCID/hu mouse activation of CD4 + helper T cells could determine bystander activation of latently infected B lymphocytes, which could be sufficient for viral reactivation and subsequent tumorigenesis. Even though in vitro evidence suggests that this might be possible, 6 whether EBV reactivation by putatively T-cell derived factor(s) in SCID/hu animals occurs or conversely that the lymphoma simply derives from the expansion of latently infected B-cell precursors present in the PBMC inoculum is as yet unexplored in vivo. In the present study, we directly address this issue, and show that EBV reactivation is not an early event in this experimental model, and that lymphomas most probably derive from the expansion of the very few latently infected B lymphocytes present in the injected cell population.
Materials and methods

Cell source and preparation
PBMC were obtained from healthy male adult volunteers undergoing lymphapheresis after their informed consent; prior EBV infection was confirmed by testing for the presence of serum anti-VCA and anti-EBNA IgG. In a set of experiments, unfractionated PBMC were initially depleted of CD8 + cells with anti-CD8 monoclonal antibody (mAb)-coated magnetic beads (Dynabeads M-450, Dynal, Oslo, Norway) according to the manufacturer's recommendations; the resulting cell population was subsequently treated with leucine-O-methyl-esther (Leu-O-ME; Sigma, St Louis, MO, USA) in order to abrogate non-MHCrestricted cytotoxic activity, as previously reported.
14 Residual contamination of CD8 + and NK cells in the recovered population did not exceed 1%, as determined by cytofluorimetric analysis with anti-CD8, anti-CD16, and anti-CD56 mAbs. Tonsillar lymphocytes were obtained from EBV-seronegative female patients (age 3-5 years) undergoing tonsillectomy; the tonsils were minced with scissors, and single-cell suspensions were prepared. Tonsillar B lymphocytes were obtained by positive selection with anti-CD19 mAb-coated microbeads (Miltenyi Biotec GmbH, Bergish Gladbach, Germany) according to the manufacturer's instructions; their purity was 499%, as assessed by flow cytometry with anti-CD19 mAb.
Mouse injection
SCID mice were purchased from Charles River (Wilmington, MA, USA), and maintained in our animal facilities under pathogen-free conditions. Procedures involving animals and their care were reported elsewhere, 15 and conformed with institutional guidelines that comply with national and international laws and policies (EEC Council Directive 86/609, OJ L 358, 12 December, 1987). Groups of five to seven mice 7 to 9-week-old were inoculated i.p. with (i) 70-100 Â 10 6 CD8 + and NK cell-depleted PBMC from a seropositive male donor, alone or in combination with 10 Â 10 6 purified tonsillar B cells from a seronegative female, (ii) 5 Â 10 6 cells of an EBV + lymphoblastoid cell line from the same seropositive individual and 5 Â 10 6 purified tonsillar B cells, (iii) 10 Â 10 6 purified tonsillar B cells, or (iv) 70-100 Â 10 6 unfractionated PBMC. In the animals inoculated with unfractionated PBMC, cells were recovered from the peritoneal cavity at variable intervals (4, 8, and 16 days) following injection, by washing the peritoneal cavity with 20 ml of RPMI 1640 medium (Life Technologies, Grand Island, NY, USA). At each time point, a three-step peritoneal lavage was performed. First, the peritoneal cavity was washed with 2 ml of cold medium. The recovered volume was centrifuged, and the cells were pooled with those obtained by a second and third washing with 9 ml of medium each. The cells were then counted and processed for RNA analysis and cytofluorimetric analysis as detailed below. At the above-mentioned time points, mesenteric lymph nodes and spleens were also collected and processed to obtain single-cell suspensions. The animals were observed daily for signs of illness (ruffled fur, respiratory distress, inactivity, weight loss, and palpable abdominal masses); when they became sick, they were killed by excess ethyl ether anesthesia and autopsied. Tumor masses were divided into three samples: one was immediately frozen in liquid nitrogen for molecular biology studies; one was fixed in paraformaldehyde/saline for histopathological and immunohistochemical studies; and the third was used for the preparation of viable cell suspensions to be used for fluorescence in situ hybridization (FISH).
Antiviral therapy
In another set of experiments, groups of five to seven mice 7-to 9-week-old were inoculated i.p. with 70-80 Â 10 6 unfractionated PBMC from EBV-seropositive donors. Ganciclovir (Sigma) was administered by a once-daily intraperitoneal injection at a dose of 25 mg/kg/day. Ganciclovir was administered starting from 24 h after PBMC transfer and continued for 42 days. Control animals were injected with an equivalent volume of phosphate-buffered saline (PBS; Gibco-BRL, Paisley, UK).
Cytofluorimetric analysis
The following mAbs were used for direct immunofluorescence: phycoerythrin (PE)-conjugated anti-CD19, fluorescein isothiocyanate (FITC)-conjugated anti-CD3, PE-anti-CD8, FITC-anti-CD16, and PE-anti-CD56 (all from Becton Dickinson, San Jose, CA, USA). Cells recovered at various time intervals from the peritoneal cavity of the SCID/hu mice were resuspended in icecold buffer (PBS-3% bovine serum albumin; Sigma) and labeled with a PE-anti-human HLA-ABC mAb (Dako, Glostrup, Denmark) for 30 min; the cells were then washed and analyzed on an EPICS-XL cytofluorimeter (Coulter, Hialeah, FL, USA), as reported elsewhere. 16 Background fluorescence was assessed by using isotype-matched mouse immunoglobulins.
Generation of lymphoblastoid cell lines (LCL)
LCL were generated as reported. 17 Briefly, PBMC (5 Â 10 6 ) were incubated with 2 ml of supernatant from the B95.8 cell line for 8 h at 371C, 5% CO 2 in air. An equal volume of RPMI 1640 medium supplemented with 10% of heat-inactivated fetal calf serum (Gibco-BRL; complete RPMI) was then added in the presence of 1 mg/ml cyclosporin A (Sandoz, Basel, Switzerland); the cell suspension was then transferred into 96-well flat bottom plates at 10 5 cells/well; the cultures were fed weekly with fresh complete RPMI, and scored for proliferation every 4-5 days.
FISH
Interphase nuclei were analysed on standard cytogenetic preparations by FISH, as previously described. 18 Briefly, tumor cell suspensions were resuspended in 0.075 M KCl hypotonic solution for 30 min. The cell suspension was fixed by three changes of a 3:1 dilution of fresh methanol-acetic acid and gently dropped onto slides. FISH analysis was performed with the following probes: a spectrum green-labeled centromeric X probe, a spectrum orange-labeled centromeric chromosome 9 probe (both from Vysis, Downers Grove, IL, USA), and a mixture of four cosmid probes 19 encompassing the major part of EBV M-ABA genome: cSAL-A, c302-23, c301-99, and c302-21 (kindly provided by Dr W Hammerschmidt, Munich, Germany). Cosmid probes were biotin-labeled by nick translation using the biotin-Nick translation mix (Roche, Mannheim, Germany). Slides were denatured for 3 min in 70% formamide-2 Â SSC at 731C in a water bath. Preparations were dehydrated with cold 70, 90, and 100% ethanol for 2 min each and air dried. For each Lack of EBV reactivation in SCID/hu mice E Piovan et al sample, 200 ng of EBV probes were denatured for 10 min at 651C and preannealed for 30 min at 371C before being mixed with spectrum green-labeled centromeric X probe in an appropriate hybridization buffer (70% formamide, 2 Â SSC, 10% dextran sulfate). Hybridization was carried out at 371C overnight in a humid chamber. Posthybridization washes were performed at 461C according to LSI protocol (Vysis). EBVspecific cosmid probes were detected with avidin-cyanine 3 (Amersham Biosciences Europe GmbH, Feiburg, Germany) diluted 1:1000 in Blocking Reagent (Roche, Milan, Italy) 1%/ 4 Â SSC. Nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI). The slides were examined with a Zeiss Axioplan fluorescent microscope equipped with a cooled charge-coupled-device (CCD) camera (Hamamatsu, Hamamatsu-city, Japan) and appropriate single band filters. Images were analyzed using CROMOFISH software (Casti Imaging, Mira-Venice, Italy). At least three tumors were analyzed for each combination of donors, and a minimum of 300 non-overlapping interphase nuclei from each tumor mass were evaluated.
RNA extraction and RT-PCR amplification
The expression of BZLF-1 was analyzed by nested polymerase chain reaction (PCR). Briefly, total cellular RNA was extracted from cells recovered at various time intervals from the peritoneal cavity and lymph nodes of the SCID mice injected with unfractionated PBMC or from tumor masses with the RNeasy mini kit (Qiagen, Hilden, Germany), according to the manufacturer's instructions. For RT-PCR, samples were pretreated with 10 U RNAse-free DNAse I (Roche, Milan, Italy) for 15 min at 371C, followed by denaturing of the enzyme for 5 min at 991C, to avoid amplification of DNA contamination. RNA was reverse transcribed using 12.5 U of AMV-RT (Promega, Madison, WI, USA) and 0.5 mg of (oligo)dT as primer for 45 min at 421C. Nested set of primers allowing distinction between expressed mRNA and contaminating genomic DNA were used for amplification of BZLF-1 from cDNA, as previously described. 6 The outer BZLF-1 primer sequences were 5 0 -ATTG-CACCTTGCCGCCACCTTTG-3 0 and 5 0 -CGGCATTTTCTG-GAAGCCACCCGA-3 0 , while the nested BZLF-1 primer sequences were 5 0 -GACCAAGCTACCAGAGTCTAT-3 0 and 5 0 -CAGAATCGCATTCCTCCAGCGA-3 0 . To confirm the presence of human B cells and detect latent EBV gene transcript expression in the cell populations recovered from the mouse peritoneal cavity and lymph nodes, we executed an RT-PCR for CD79b, a B-cell specific transcript, 20 and for the small noncoding EBER-1 RNA. 2 For the control of RNA and cDNA preparations, we used RT-PCR for b actin, as previously described. 21 In order to test the sensitivity of our PCR assay for BZLF-1, a freshly generated LCL was used for titration assays with an increasing number of cells of the EBV À cell line 293T (obtained from ATCC). Briefly, a series of 10-fold dilutions of LCL cells (from 2 Â 10 6 to 2) were added to a background of EBV À 293T cells to generate samples containing a total of 2 Â 10 6 cells before RNA extraction and RT-PCR.
Statistical analysis
Statistical comparison of experimental categories was performed with the log-rank test for analysis of mortality data, with Po0.05 considered significant.
Results
No evidence of early expression of BZLF-1 transcript in cells recovered from the mouse peritoneal cavity
One group of SCID mice was injected i.p. with 70-100 Â 10 6 unfractionated PBMC, and cells were recovered from the peritoneal cavity at 4, 8, and 16 days after injection. Cells were in part examined by flow cytometry using mAbs to identify human (ie HLA-ABC + ) cells, and in part used for RNA extraction. As also reported by others, 22 the number of human cells recovered from the mouse peritoneal cavity was low; as illustrated in Figure 1 , cytofluorimetric analysis demostrated that 4 days after the injection of PBMC approximately 35% of the cell population recovered (10 Â 10 6 ) was human; this percentage fell to 22% of the total cell population recovered (6 Â 10 6 ) after 8 days. At 16 days after injection, the cell population recovered (1.5 Â 10 6 ) was almost entirely murine ( Figure 1 ). In view of the possibility that transferred human B cells could preferentially home to mouse abdominal lymphoid tissues, for the subsequent PCR analysis cells recovered from the peritoneal cavity of several mice at the above-mentioned time points were pooled together with the single-cell suspensions obtained from abdominal lymph-nodes and evaluated for the expression of latent (EBER-1) and lytic (BZLF-1) markers. As shown in Figure 2 , the latent EBV transcript, EBER-1, could readily be detected at all time points considered (lanes 1-4); in addition, a band corresponding to CD79b was clearly evident in all samples tested, thus indicating that human B cells were in fact present within samples (Figure 2, lanes 1-4) . Notwithstanding, no evidence of BZLF-1 expression could be detected (Figure 2,  lanes 1-4) ; in contrast, tumor masses consistently expressed both EBER-1 and BZLF-1 (Figure 2, lanes 5-7) .
These data seemed to indicate that the reactivation of EBV was not detectable early after PBMC transfer into SCID mice. However, we could not exclude that our nested PCR assay was not sensitive enough to detect BZLF-1 transcripts from the small number of EBV + B-cell precursors, putatively estimated as about 20-600, 13 present within PBMC inocula. We thus felt it necessary to define the sensitivity of our PCR assay; to this 23 these figures roughly correspond to two to four lytically infected LCL cells. Thus, the sensitivity of our nested PCR assay for BZLF-1 detection seems to be rather high; within these limits, we were not able to detect in vivo virus replication, at least during the very early phases of tumor generation.
Coinjection of PBMC from seropositive male donors with B cells from seronegative female donors does not give rise to mixed tumors
To confirm these data, we directly addressed the possibility of EBV reactivation in PBMC-injected SCID mice and virus spread to noninfected bystander B lymphocytes by a different strategy. PBMC from EBV-seropositive donors and B cells from seronegative donors of different sex were coinjected into SCID animals. In order to eliminate the risk of a cytolytic reaction against the coinjected allogeneic B cells, PBMC from seropositive male donors were preliminarily depleted of CD8 + T lymphocytes and NK cells. The resulting tumor masses were dissociated and used to perform FISH analysis with probes specific for the sexual chromosome X and EBV genome. As previously reported, [7] [8] [9] [10] [11] 24 tumors developed within 7-12 weeks in 80% of mice injected with PBMC from the seropositive donors; as expected, 10 removal of CD8 + and NK cells from the inoculum did not give a significant change in tumor incidence (83%), and no tumor masses developed in SCID mice injected with tonsil B cells, thus confirming the EBV seronegative status of the donor.
By FISH analysis of tumor masses, the overwhelming majority of fields analyzed showed cells reactive for one X chromosome (green signal) and a variable number of copies of EBV DNA (red signal), highlighting the almost exclusive presence of male EBV + cells ( Figure 4, Panel a) . Only one to two out of 300 nuclei showed the presence of two green signals and red signals within the same cell, suggesting the presence of female EBV + cells (Figure 4, Panel b, arrow) . However, it was also possible that these cells could originate from endoreduplication of male EBV + cells, a phenomenon where the replication of DNA during the S phase of the cell cycle is not followed by the subsequent completion of mitosis and/or cytokinesis; 25, 26 to address this possibility we used probes specific for the centromeric region of chromosome 9 and for the centromeric region of chromosome X (Figure 4 , Panel C). All cells harboring two X chromosomes (green signals) were found to present four copies of chromosome 9 (red signals; Figure 4c , arrow), thus implying that endoreduplication had indeed occured in some immortalized B lymphocytes from the male donor. On the other hand, as illustrated in Figure 4 (Panel D), the tumor masses generated after coinjection of LCL cells obtained from the male donors and seronegative female B cells were of mixed origin, demonstrating that the latter were able to survive long-enough to undergo immortalization; indeed, the EBV-positive cells (red spotted cells) presented a male (one green signal) to female (two green signals) ratio of approximately 1:1 (5875% male cells, and 4277% female cells). This clearly indicates that EBV can actually be transmitted in vivo to neighboring susceptible cells, provided that an adequate proportion of infected B lymphocytes express lytic EBV antigens early after in vivo transfer.
Antiviral therapy does not inhibit tumor development
To further corroborate our results and definitively answer the question whether horizontal transmission of virus is required for tumor development, PBMC from EBV-positive donors were inoculated into SCID mice and treated with once-daily intra- Lack of EBV reactivation in SCID/hu mice E Piovan et al peritoneal injection of ganciclovir for 42 days, beginning 24 h after engraftment. Treatment with ganciclovir had no effect on the development of lymphoma in these animals ( Figure 5 ; P ¼ not significant), implying that in vivo EBV replication has a minor role in lymphoma generation in this experimental model.
Discussion
EBV-associated PTLD carries a high mortality rate; 27 the therapeutic options reported in the literature have been varied, ranging from mere reduction in immunosuppression to aggressive combination chemotherapy. 28, 29 The SCID mouse is a suitable animal model for studying the mechanisms underlying EBV-associated lymphoproliferation; PBMC from EBV-seropositive healthy donors give rise to EBV + tumor masses in a proportion of animals. 8, 9 The presence of T lymphocytes within the inoculum is essential for tumor development. 10, 11 It is probable that after PBMC transfer in SCID mice, T cells undergo activation and produce cytokines, 10, 11, 30 which in turn stimulate the expansion of B cells, including latently EBV-infected lymphocytes; these latter, thanks to the growth advantage conferred by the presence of EBV genome, undergo preferential expansion, leading to tumor mass generation and death of the animal. However, it is also conceivable that EBV-infected B cells enter the productive cycle after in vivo transfer, possibly driven by T-cell-derived factor(s), with release of the virus that infects and transforms other resting B lymphocytes, eventually contributing to lymphoma generation. Interestingly, it has been recently demonstrated that activated T cells are able in vitro to turn on EBV replication in latently infected B lymphocytes, as shown by BZLF-1 expression. 6 In view of this, the aim of the present study was to investigate the contribution of newly infected B cells to tumor outgrowth in SCID/hu mice, which could explain the rationale for acyclovir/ganciclovir prophylaxis (which inhibit the lytic but not latent form of EBV infection) for PTLD in transplant patients. 31 ,32 Effect of long-term administration of ganciclovir (GCV) on lymphoma development in SCID/hu mice. Mice received oncedaily by intraperitoneal injection either 25 mg/kg of GCV or PBS starting from 24 h after PBMC transfer for 42 days. Results of one of three consecutive experiments are shown.
Lack of EBV reactivation in SCID/hu mice E Piovan et al Our experimental design was initially to investigate by RT-PCR the expression of BZLF-1 as an indicator of EBV reactivation in cells recovered at different time intervals from SCID mice inoculated with unfractionated PBMC. BZLF-1 transcript could not be detected at any of the early time points studied (days 4, 8, and 16 after injection), but only in the tumor masses present at killing (Figure 1 ), indicating that EBV reactivation is a modest and late phenomenon rather than an early event. In contrast, latent transcript expression, as evidenced by EBER-1 production, was readily detectable at all early time points, suggesting a predominant role for the expansion of latently EBV-infected B lymphocytes in lymphoma generation in this experimental model.
In order to better substantiate our findings, we adopted a completely different approach. PBMC from male seropositive donors were depleted of CD8 + and NK cells (to abrogate their cytotoxic activity), and coinjected with purified tonsil B lymphocytes from seronegative donors of different sex. The subsequent tumor masses were analyzed by FISH with probes specific for the sexual chromosome X and EBV genome. FISH examination of the tumor masses disclosed that the overwhelming majority of EBV + cells were of male origin (Figure 4a ), implying that no significant in vivo infection of female tonsil B lymphocytes occurred. Very seldom, cells harboring two X chromosomes and the EBV genome were encountered (1-2/300 nuclei), suggesting the presence of female EBV + cells. However, these cells could also be male EBV + cells that have undergone DNA replication without the subsequent completion of mitosis (endoreduplication). 25, 26 Indeed, when this possibility was investigated using probes specific for an autosome (chromosome 9) and chromosome X, cells containing two copies of the X chromosome were found to contain four copies of chromosome 9, evidencing endoreduplication. To investigate whether the observed lack of in vivo virus transmission to EBV negative B cells was due to their accelerated clearance or a lack of susceptibility to EBV infection, we coinjected LCL cells (which produce low but detectable levels of lytic transcripts, such as BZLF-1) of the same seropositive donor with tonsillar B lymphocytes from a seronegative donor of different sex. FISH analysis of the resulting masses disclosed that they were made out of male (one X chromosome) and female (two X chromosomes) EBV + cells in almost equal proportion (Figure 4d ), demonstrating that EBV can actually be transmitted in vivo in this experimental model, when an adequate proportion of infected B cells express early EBV activation antigens.
To further substantiate our findings, we investigated whether the antiviral drug, ganciclovir, which inhibits the lytic (but not latent) form of EBV replication, could inhibit lymphoma generation. As could be expected from the above results, ganciclovir administration did not prevent lymphoma development, suggesting that horizontal transmission of the virus has indeed a minimal impact on lymphoma generation in this experimental model. These data confirm and extend previous observations on the effect of acyclovir/ganciclovir on tumor development in the SCID mouse; as recently reported, 33 in fact, no antiviral drug effect was recorded in these animals, and the tumor-preventing activity was only observed in mice treated with EBV-reactivating agents such as sodium butyrate or g-irradiation.
Overall, our in vivo results are partially in contrast with recently published in vitro evidence, 6 showing that EBV-specific CD4 + T lymphocytes can provide non-HLA-restricted help for activation of resting B cells via a CD40:CD40L-dependent pathway, and are able to induce BZLF-1 expression and eventual virus release, which in turn leads to rapid in vitro outgrowth of transformed B cells. These same authors postulated that in the SCID/hu mouse, activation of CD4 + helper T cells of any specificity (eg through graft-versus-host responses) and eventual CD40L expression could determine bystander activation of latently infected B lymphocytes, which could in turn be sufficient for viral reactivation and subsequent tumorigenesis. While our molecular and in vivo data do not support this notion, B-cell activation induced by engagement of CD40 with anti-CD40 mAb (which surrogates the function of CD40L expressed on activated T cells) has been shown to inhibit (rather than to promote) lymphomagenesis in the PBMC-injected mouse, 34 thus questioning the possible favouring role of this pathway in EBV reactivation of latently infected B cells, and substantiating our in vivo results. Altogether, although the issue of the mechanisms underlying the tumor-promoting activity of T lymphocytes in this experimental model remains open, our results suggest that in the development of tumor masses in the SCID/hu mouse early EBV replication and infection of bystander B cells does not occur at detectable levels, and that direct outgrowth of transformed B cells may be the predominant if not exclusive mechanism that leads to lymphoma generation.
